γδ T Cell Cancer Immunotherapy

English | 2025 | PDF | 10 MB | 197 Pages

Marta Barisa, 9780443217661, 978-0443217661, 978-0-443-21766-1, 0443217661, 044321767X, 9780443217678, 978-0443217678

γδ T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation sets out and critically discusses the current clinical and relevant preclinical γδ T cell immunotherapy landscape. In five chapters, field experts discuss the challenges facing γδ T cell oncoimmunotherapy, propose solutions, and map next steps. Particular attention is given to summarizing our understanding of the complex, translationally relevant human γδ T cell biology, the evidence basis for designing γδ T cell combination trials and data-driven perspectives on what is known―and what isn’t―about γδ T cell therapeutic persistence. Various perspectives are provided on how issues of cytotoxic effector function, functional exhaustion, and cytokine addiction can be mitigated using gene engineering. A chapter is dedicated to the systematic review of all γδ T cell immunotherapy trials to date, and the cell therapy products that were used in these trials. The final chapter discusses allograft persistence-enhancement techniques in the context of γδ T cell therapy, covering lymphodepleting chemotherapy and synthetic stealth engineering. γδ T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation gives an updated and comprehensive insight into the current state of γδT cell immunotherapy, which is of interest to existing translational γδ T cell specialists, the proliferating range of academic scientists and commercial scientists entering the field, as well as clinicians who may encounter γδ T cell immunotherapy in the clinic, or are wishing to familiarize themselves with noncanonical lymphocyte immunotherapy.

• Summarizes the cutting edge of oncology-relevant γδ T cell immunobiology
• Lays out clinical successes and failures to date
• Addresses the possible advantage of combining γδ T cell-based immunotherapy with conventional chemotherapy or checkpoint blockers
• Provides an up-to-date and well-rounded discussion of a translationally, commercially, and scientifically relevant field